Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination

Annals of the Rheumatic Diseases

Volumn 68, Issue 6, 2009, Pages 873-878

  Holvast, A ^a   Stegeman, C A ^a   Benne, C A ^b   Huckriede, A ^a   Wilschut, J C ^a   Palache, A M ^c   Kallenberg, C G M ^a   Bijl, M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Laboratory for Infectious Diseases   (Netherlands)

^c Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DRUG FEVER; DRUG INDUCED HEADACHE; ERYTHEMA; FEMALE; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; MALE; MYALGIA; NAUSEA; PAIN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEROCONVERSION; SHIVERING; SKIN INDURATION; VIRUS STRAIN; WEGENER GRANULOMATOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, VIRAL; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; ORTHOMYXOVIRIDAE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 67449143745     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.092924     Document Type: Article

References (36)

1. Harper L, Savage CO. ANCA-associated renal vasculitis at the end of the twentieth century - a disease of older patients. Rheumatology (Oxford) 2005;44:495-501. (Pubitemid 41511141)
2. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-498
3. World Health Organization. Influenza vaccines. Wkly Epidemiol Rec 2005;80:279-287
4. Holvast A, Huckriede A, Wilschut J, Horst G, De Vries JJ, Benne CA, et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis 2006;65:913-918
5. Abu-Shakra M, Press J, Varsano N, Levy V, Mendelson E, Sukenik S, et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol 2002;29:2555-2557 (Pubitemid 35416961)
6. Gangappa S, Kokko KE, Carlson LM, Gourley T, Newell KA, Pearson TC, et al. Immune responsiveness and protective immunity after transplantation. Transplant Int 2008;21:293-303. (Pubitemid 351348020)
7. Abu-Shakra M, Press J, Buskila D, Sukenik S. Influenza vaccination of patients with systemic lupus erythematosus: safety and immunogenecity issues. Autoimmun Rev 2007;6:543-546 (Pubitemid 47374614)
8. Stassen PM, Sanders JS, Kallenberg CG, Stegeman CA. Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis. Nephrol Dial Transplant 2008;23:654-658 (Pubitemid 351767630)
9. Cannata J, Cuesta V, Peral V, Maisueche I, Herrera J. Reactivation of vasculitis after influenza vaccination. BMJ (Clin Res Ed) 1981;283:526. (Pubitemid 11040539)
10. Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990;33:1101-1107
11. Tervaert JW, Mulder L, Stegeman C, Elema J, Huitema M, The H, et al. Occurrence of autoantibodies to human leucocyte elastase in Wegener's granulomatosis and other inflammatory disorders. Ann Rheum Dis 1993;52:115-120
12. Harmon MW. Influenza viruses. In: Lennette, ed. Laboratory diagnosis of viral infections, 2nd ed. New York: Marcel Dekker, 2004:515-534
13. de Jong JC, Ronde-Verloop FM, Veenendaal-van Herk TM, Weijers TF, Bijlsma K, Osterhaus AD. Antigenic heterogeneity within influenza A (H3N2) virus strains. Bull WHO 1988;66:47-55. (Pubitemid 18116821)
14. European Agency for the Evaluation of Medicinal Products (EMEA), Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96), 12 March 1997. http://www.emea.europa.eu/pdfs/human/bwp/021496en.pdf (accessed Feb 2009).
15. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995;123:518-527
16. Duchini A, Hendry RM, Nyberg LM, Viernes ME, Pockros PJ. Immune response to influenza vaccine in adult liver transplant recipients. Liver Transpl 2001;7:311-313 (Pubitemid 32331534)
17. Mazzone PJ, Mossad SB, Mawhorter SD, Mehta AC, Schilz RJ, Maurer JR. The humoral immune response to influenza vaccination in lung transplant patients. Eur Respir J 2001;18:971-976 (Pubitemid 34092871)
18. Soesman NM, Rimmelzwaan GF, Nieuwkoop NJ, Beyer WE, Tilanus HW, Kemmeren MH, et al. Efficacy of influenza vaccination in adult liver transplant recipients. J Med Virol 2000;61:85-93. (Pubitemid 30191231)
19. Isenberg D, Rahman A. Systemic lupus erythematosus - 2005 annus mirabilis? Nat Clin Pract Rheumatol 2006;2:145-152
20. Kallenberg CG, Heeringa P, Stegeman CA. Mechanisms of disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol 2006;2:661-670 (Pubitemid 44830855)
21. Govaert TM, Sprenger MJ, Dinant GJ, Aretz K, Masurel N, Knottnerus JA. Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trial. Vaccine 1994;12:1185-1189
22. Gross PA, Sperber SJ, Donabedian A, Dran S, Morchel G, Cataruozolo P, et al. Paradoxical response to a novel influenza virus vaccine strain: the effect of prior immunization. Vaccine 1999;17:2284-2289 (Pubitemid 29225680)
23. Pyhala R, Kumpulainen V, Alanko S, Forsten T. HI antibody kinetics in adult volunteers immunized repeatedly with inactivated trivalent influenza vaccine in 1990- 1992. Vaccine 1994;12:947-952
24. Keitel WA, Cate TR, Couch RB. Efficacy of sequential annual vaccination with inactivated influenza virus vaccine. Am J Epidemiol 1988;127:353-364 (Pubitemid 18056387)
25. Keitel WA, Cate TR, Couch RB, Huggins LL, Hess KR. Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine 1997;15:1114-1122 (Pubitemid 27357195)
26. de Bruijn I, Remarque EJ, Jol-van der Zijde CM, van Tol MJ, Westendorp RG, Knook DL. Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination. J Infect Dis 1999;179:31-36 (Pubitemid 29028335)
27. de Bruijn I, Remarque EJ, Beyer WE, le Cessie S, Masurel N, Ligthart GJ. Annually repeated influenza vaccination improves humoral responses to several influenza virus strains in healthy elderly. Vaccine 1997;15:1323-1329
28. Smith DJ, Forrest S, Ackley DH, Perelson AS. Variable efficacy of repeated annual influenza vaccination. Proc Natl Acad Sci U S A 1999;96:14001-14006
29. Nabeshima S, Kashiwagi K, Murata M, Kanamoto Y, Furusyo N, Hayashi J. Antibody response to influenza vaccine in adults vaccinated with identical vaccine strains in consecutive years. J Med Virol 2007;79:320-325 (Pubitemid 46213197)
30. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44. (Pubitemid 36765101)
31. Seo P, Min YI, Holbrook JT, Hoffman GS, Merkel PA, Spiera R, et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 2005;52:2168-2178 (Pubitemid 40994340)
32. Jayne DR, Gaskin G, Pusey CD, Lockwood CM. ANCA and predicting relapse in systemic vasculitis. Q J Med 1995;88:127-133
33. Boomsma MM, Stegeman CA, van der Leij MJ, Oost W, Hermans J, Kallenberg CG, et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000;43:2025-2033 (Pubitemid 30953265)
34. Finkielman JD, Merkel PA, Schroeder D, Hoffman GS, Spiera R, St Clair EW, et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 2007;147:611-619 (Pubitemid 351664480)
35. Beyer WE, de Bruijn I, Palache AM, Westendorp RG, Osterhaus AD. Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. Arch Intern Med 1999;159:182-188 (Pubitemid 29055107)
36. Voordouw AC, Sturkenboom MC, Dieleman JP, Stijnen T, Smith DJ, van der Lei J, et al. Annual revaccination against influenza and mortality risk in community-dwelling elderly persons. JAMA 2004;292:2089-2095 (Pubitemid 39435099)